HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. (Q40397252)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Lenka Dubská

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ladislav Andera

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

English

0 references

publication date

1 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

FEBS Letters

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

579

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

4149-4158

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023111%20AND%20SRC:MED&resulttype=core&format=json

The TRAIL to selective tumor death

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

First-line Herceptin monotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Resistance to trastuzumab: a necessary evil or a temporary challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Heregulin regulation of Akt/protein kinase B in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.047